Press

Publication / PharmacoEconomics Open 04.23.2025

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan
Publication / Microorganisms 03.15.2025

Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)
Publication / BMC Pregnancy and Childbirth 02.26.2025

Maternal and fetal survival following Ebola, HIV and Malaria co-infection in the first trimester of gestation in resource-limited setting in Democratic Republic of Congo
Publication / Center for Infectious Disease Research and Policy 11.20.2024

Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
Publication / Italian Journal of Medicine 06.03.2024

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study
Publication / The Journal of Infection in Developing Countries 05.30.2024

Molnupiravir’s real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
Publication / Infectious Diseases and Therapy 05.14.2024

Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review
Publication / Journal of Clinical Medicine 04.16.2024

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic
Publication / Clinical and Translational Science 02.08.2024

Molnupiravir: Mechanism of action, clinical, and translational science
Publication / Microbiology Spectrum 02.01.2024

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
Publication / Infectious Diseases and Therapy 01.17.2024

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
Publication / Antimicrobial Agents and Chemotherapy 12.04.2023

Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance
Publication / Clinical Infectious Diseases 12.01.2023

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
Publication / Infectious Diseases and Therapy 11.23.2023

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Publication / Frontiers In Pharmacology 11.15.2023

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
Press Release / HHS 10.27.2023

Letter to COVID-19 therapeutics manufacturers, distributors, pharmacies and the health care payer community
Publication / CPT: Pharmacometrics & Systems Pharmacology 10.05.2023

Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals
Press Release / HHS – ASPR 09.29.2023

Lagevrio Prepares for Transition to Commercial Distribution
Publication / JAMA Network Open 09.21.2023

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
Publication / Journal of Infection 09.08.2023

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial
Publication / Clinical Therapeutics 08.17.2023

Hospitalization Among Patients Treated With Molnupiravir: A Retrospective Study of Administrative Data
Publication / Epidemiologia 08.10.2023

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
Publication / Clinical and Translational Science 08.01.2023

Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants
Publication / Cureus 05.05.2023

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A MetaAnalysis
Publication / Clinical Pharmacology & Therapeutics 04.05.2023

Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes
Publication / Infectious Diseases and Therapy 03.16.2023

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
Publication / Frontiers in Pharmacology 03.08.2023

Ebanga™: The most recent FDA-approved drug for treating Ebola
Publication / Drug Design, Development and Therapy 01.19.2023

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
Publication / Infection 01.17.2023

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Media / Global Times 01.15.2023

1st batch of Molnupiravir available at mainland hospitals as new option for COVID-19 patients
Media / The Mighty 790 KFGO 01.10.2023

Ridgeback Biotherapeutics and Merck’s COVID treatment expected to launch in China on Friday
Media / Clinical Trials Arena 12.22.2022

Excellence Awards 2022 – Winners Announced!
Publication / Clinical and Experimental Medicine 12.05.2022

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Media / Chemical & Engineering News 12.01.2022

ACS celebrates its 2022 Heroes of Chemistry including Ridgeback Biotherapeutics
Publication / Cureus 11.14.2022

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
Press Release / Open PR 11.07.2022

COVID-19 Oral Medicine Market Trends, Analysis and Forecast till 2028 | Key Players Novartis AG, Merck & Co, Atea Pharmaceuticals, Ridgeback Biotherapeutics, Pfizer Inc
Media / SHINE 11.05.2022

Biopharmaceutical ‘writing our future’ at CIIE
Publication / The Lancet Infectious Diseases 10.19.2022

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Press Release / Bloomberg 10.06.2022

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
Publication / Clinical and Translational Science 08.31.2022

A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19
Publication / Clinical Infectious Diseases 08.24.2022

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Media / Reuters 08.19.2022

WHO recommends use of two antibody drugs against Ebola
Press Release / GlobeNewswire 07.07.2022

Wendy Holman’s Ridgeback Biotherapeutics and Emergent BioSolutions Enter Into Agreement for Ebanga™ Treatment for Ebola
Publication / PharmacoEconomics 07.02.2022

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
Press Release / Business Wire 06.07.2022

Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
Publication / Annals of Internal Medicine 06.07.2022

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Press Release / Business Wire 04.01.2022

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Publication / The New England Journal of Medicine 03.23.2022

Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020
Media / Bloomberg 03.02.2022

Ridgeback Biotherapeutics and Merck’s Covid Antiviral Gets WHO Backing for High-Risk Patients
Media / New York Times 02.20.2022

A Covid pill developed with the help of Ridgeback Biotherapeutics reduces the risk of hospitalization
Publication / Drugs 02.20.2022

Molnupiravir: First Approval
Press Release / Business Wire 02.08.2022

Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
Press Release / Business Wire 01.28.2022

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
Media / Reuters 01.21.2022

Dozens of firms to make cheap version of Merck COVID pill for poorer nations
Publication / Science Translational Medicine 01.19.2022

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
Press Release / Merck 01.18.2022

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Press Release / Business Wire 12.24.2021

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Press Release / Business Wire 12.23.2021

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
Press Release / Business Wire 12.22.2021

Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
Media / The Wall Street Journal 12.20.2021

Behind a New Pill to Treat Covid: Wayne and Wendy Holman and a Hunch that led to its creation
Press Release / Business Wire 12.16.2021

Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
Publication / The New England Journal of Medicine 12.16.2021

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Publication / NEJM Evidence 12.16.2021

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
Media / Fortune 12.01.2021

Antiviral pill developed in partnership between Merck and Wendy Holman’s, Ridgeback Biotherapeutics, are likely to maintain efficacy against the Omicron COVID variant— even if vaccines don’t
Press Release / Business Wire 11.30.2021

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
Press Release / Business Wire 11.26.2021

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Press Release / Business Wire 11.17.2021

Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
Publication / Journal of Antimicrobial Chemotherapy 11.12.2021

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Press Release / Business Wire 11.10.2021

Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
Press Release / Business Wire 11.09.2021

Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
Media / The Washington Post 11.04.2021

Britain is the first country to authorize the antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics to treat coronavirus
Media / Wall Street Journal 11.04.2021

Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization
Press Release / Business Wire 11.04.2021

Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
Media / New York Times 10.27.2021

Licensing deal will allow poor countries to manufacture and sell cheaply the Covid-19 pill, developed by Merck in partnership with Wendy Holman’s Ridgeback Biotherapeutics
Press Release / Business Wire 10.27.2021

The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
Press Release / Business Wire 10.25.2021

Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
Media / New York Times 10.20.2021

Gates Foundation pledge to help poor countries by supplying them with Covid pill that was developed in record time by Ridgeback Biotherapeutics and Merck
Media / Reuters 10.20.2021

Gates Foundation allots $120 mln for poor nations to get COVID-19 drug
Press Release / Business Wire 10.20.2021

Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo
Press Release / Business Wire 10.11.2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
Media / CNBC 10.06.2021

Dr. Gottlieb sees Covid’s ‘pandemic phase’ ending when antiviral pills, kids’ vaccines available
Media / Reuters 10.04.2021

Merck pill seen as ‘huge advance,’ raises hope of preventing COVID-19 deaths
Media / Politico 10.03.2021

Fauci sees hope in new Merck drug
Media / Yahoo News 10.01.2021

Fauci says new pill ‘impressive’ at keeping COVID patients alive and out of hospitals
Media / Washington Post 10.01.2021

Merck’s experimental pill to treat covid-19 cuts risk of hospitalization and death in half, the pharmaceutical company reports
Media / USA Today 10.01.2021

New antiviral is highly effective, study finds, and is stirring hope that COVID-19 could be treated by a pill
Media / Bloomberg 10.01.2021

Merck’s New Antiviral Promises to Make Covid Less Deadly
Media / Wall Street Journal 10.01.2021

Merck Pill Intended to Treat Covid-19 Succeeds in Key Study
Press Release / Business Wire 10.01.2021

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Media / CNBC, Squawk on the Street 10.01.2021

Ridgeback Biotherapeutics co-founders, Wayne and Wendy Holman, on how a pill can tackle Covid-19
Press Release / Business Wire 09.01.2021

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Publication / Frontiers in Immunology 08.30.2021

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
Publication / Trials 08.23.2021

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
Press Release / Business Wire 07.12.2021

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Presentation / National Organization for Rare Disorders (NORD) 07.02.2021

2021 Industry Innovation Award for EBANGA
Publication / Current Opinion in Virology 06.18.2021

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
Media / New York Times 06.17.2021

U.S. invests in antiviral Covid-19 pills developed by Merck and Ridgeback Biotherapeutics
Media / Reuters 06.16.2021

Merck says study shows COVID-19 drug causes quick reduction in virus
Media / PBS 06.01.2021

Scientists hope they’re closing in on a cure for COVID-19
Press Release / Business Wire 05.15.2021

Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
Press Release / Business Wire 04.27.2021

Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
Press Release / Business Wire 04.15.2021

Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir
Media / Bloomberg 03.25.2021

Wendy Holman, CEO of Ridgeback Biotherapeutics partners with Merck to develop pill that can Transform the Fight Against Covid
Publication / Drugs 03.22.2021

Ansuvimab: First Approval
Media / Medscape 03.08.2021

Five-Day Course of Oral Antiviral Appears to Stop SARS-CoV-2 in Its Tracks
Media / CNBC 03.08.2021

Squawk on the Street
Media / Fox News 03.07.2021

COVID-19 pill effective in preliminary testing may be ‘holy grail’ of pandemic, Dr. Marc Siegel says
Presentation / CROI 03.06.2021

Reduction in Infectious SARS-CoV-2 in a Treatment Study of COVID-19 with Molnupiravir
Press Release / Business Wire 03.06.2021

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Media / Bloomberg 03.06.2021

Ridgeback Biotherapeutics LP encouraged by preliminary data from a Phase 2a trial of its Covid-19 oral antiviral treatment Molnupiravir
Media / Wall Street Journal 03.06.2021

Covid-19 Pill developed by Ridgeback Biotherapeutics LP and Merck & Co., Shows Promise in Preliminary Testing
Press Release / Business Wire 03.03.2021

Ridgeback Biotherapeutics Announces Publication of Phase 1 Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Molnupiravir in Healthy Volunteers
Publication / Antimicrobial Agents and Chemotherapy 03.01.2021

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
Media / NIH – Intramural Research Program Blog 02.10.2021

An Ebola Therapy Two Decades in the Making
Presentation / Fierce JPM Week 01.11.2021

In-development COVID-19 therapeutics
Media / NIH Director’s Blog 01.02.2021

mAB114: Celebrating 2019 Biomedical Breakthroughs
Media / Pharma Times 12.24.2020

Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval
Press Release / Business Wire 12.22.2020

Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
Media / BioPharma Dive 12.22.2020

FDA grants approval to Ebola drug from Ridgeback Biotherapeutics
Media / Endpoints News 12.22.2020

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback’s Ebanga
Media / FiercePharma 12.22.2020

Led by CEO Wendy Holman, Ridgeback Biotherapeutics develops Ebanga to treat Ebola
Media / FDA 12.21.2020

FDA Approves Treatment for Ebola Virus
Media / Drug Target Review 12.04.2020

Oral drug blocks SARS-CoV-2 transmission in ferrets, researchers find
Press Release / Business Wire 08.28.2020

Ridgeback Biotherapeutics LP Announces Initiation of Expanded Access Protocol for Ebola Treatment Ansuvimab
Media / CNBC 07.31.2020

Merck aims to start ‘large pivotal’ studies on coronavirus treatment in September
Press Release / Business Wire 07.29.2020

Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment
Press Release / Business Wire 07.07.2020

Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial
Media / PharmaPhorum 07.07.2020

UK trial begins testing second-wave COVID-19 drug from US biotech Ridgeback
Press Release / Business Wire 07.01.2020

Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Press Release / Business Wire 06.19.2020

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19
Media / Financial Times 06.16.2020

US biotech group to trial Covid-19 pill for use at home
Press Release / Business Wire 05.26.2020

Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Press Release / PR Newswire 04.13.2020

Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19 and the Start of Phase 1
Press Release / PR Newswire 04.06.2020

FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19
Press Release / PR Newswire 03.19.2020

Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment
Publication / The New England Journal of Medicine 11.27.2019

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Media / New York Times 08.12.2019

New Treatment developed by Ridgeback Biotherapeutics to fight against Ebola, Proves Highly Effective in Congo
Publication / The Lancet 03.02.2019

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

Search this site

Press

Filter by Type